Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice

Journal of Inflammation

Volumn 46, Issue 2, 1996, Pages 86-97

  Georgopoulos, Spiros ^a   Plows, David ^a   Kollias, George ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

autoimmunity; cytokine; disease model; lymphocyte; TNF

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; HISTOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS; BASE SEQUENCE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HUMANS; LYMPHOID TISSUE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNOVITIS; T-LYMPHOCYTES; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029891052     PISSN: 10787852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Vassal! P: The pathophysiology of tumour necrosis factors. Annu Rev Immunol 10: 411-452, 1992.
2. Peck R, Brockhaus M, Frey JR: Cell surface tumour necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells. Cell Immunol 122: 1-10, 1989.
3. Suttles J, Miller RW, Tao X, Stout RD: T cells which do not express membrane tumour necrosis factor a activate macrophage effector function by cell contactdependent signalling of macrophage tumour necrosis factor ex production. Eur J Immunol 24: 1736-1742, 1994.
4. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S: Membrane tumour necrosis factor a is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 363: 464-466, 1993.
5. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M: A non-secretable cell surface mutant of tumour necrosis factor (TNF) kills by cell to cell contact. Cell 63: 251-258, 1990.
6. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Voucolo G, Wolfe A, Socher SH: Tumours secreting human tumour necrosis factor/cachectin induce cachexia in mice. Cell 50: 555, 1987.
7. Beutler B, Milsark IW, Cerami AC: Passive immunisation against cachectin/tumour necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869, 1985.
8. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234: 470, 1986.
9. Piguet PF, Grau GE, Allet B, Vassalli P: Tumour necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166: 1280, 1987.
10. Grau GE, Piguet PF, Vassalli P, Lambert PH: Tumour necrosis factor and other cytokines in cerebral malaria: experimental and clinical data. Immunol Rev 112: 49, 1989.
11. Osborn L, Kunkel S, Nabel GJ: Tumour necrosis factor a and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor KB. Proc Natl Acad Sei USA 86: 2336, 1989.
12. Hofman FM, Hinton DR, Johnson K, Merrill JE: Tumour necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607-612, 1989.
13. Held W, Macdonald HR, Weissman IL, Hess MW, Mueller C: Genes encoding tumour necrosis factor a and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sei USA 87: 2239-2243, 1990.
14. Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA: Detection of tumour necrosis factor a but not tumour necrosis factor in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31: 1041, 1988.
15. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 13: 4025-4031, 1991.
16. Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G: Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumour necrosis factor transgenes. J Immunol 151: 1894-1906, 1993.
17. Mizushima S, Nagata S: pEF-BOS: a powerful mammalian expression vector. Nucleic Acids Res 18: 53225324, 1990.
18. Smith DB, Johnson KS: Single-step purification of polypeptides expressed in Escherichia coli as fusions with gluthathione S-transferase. Gene 67: 31-40, 1988.
19. Tybulewicz VLJ, Crawford CE, Jackson PK, Bronson RT, Mulligan RC: Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65: 1153-1163, 1991.
20. Greaves DR, Wilson FD, Long G, Kioussis D: Human CD2 3′-flanking sequences confer high-level, T cellspecific, position independent gene expression in transgenic mice. Cell 56: 979, 1987.
21. Hogan B, Costantini F, Lacey E: "Manipulating the Mouse Embryo. A Laboratory Manual." New York: Cold Spring Harbor Laboratory Press, 1991.
22. Brinster RL, Chen HY, Trumbauer ME, Yagle MK, Palmiter RD: Factors affecting the efficiency of introducing foreign DMA into mice by microinjecting eggs. Proc Natl Acad Sei USA 82: 4438, 1985.
23. Pasparakis M, Kollias G: Production of cytokine transgenic and knockout mice. In Balkwill FR (ed): "Cytokines: A Practical Approach." Oxford: IRL Press, 1995, pp 297-324.
24. Southern EM: Detection of specific sequences among DMA fragments separated by gel electrophoresis. J Mol Biol 98: 503, 1975.
25. Matthews N, Neale ML: Cytotoxicity assays for tumour necrosis factor and lymphotoxin. In Clemens MJ, Morris AG, Gearing AJH (eds): "Lymphokines and Interferons, A Practical Approach." Oxford: IRL Press, 1987, pp 221-225.
26. Auffray C, Rougeon F: Purification of mouse immunoglobulin mRNAs from total myeloma tumour RNA. Eur J Biol 107: 303, 1980.
27. Kollias G, Wrighton N, Hurst J, Grosveld F: Regulated expression of human Ay-, -, and hybrid y-globin genes in transgenic mice: manipulation of the developmental expression patterns. Cell 46: 89, 1986.
28. Kioussis D, Wilson F, Daniels C, Leveton C, Taverne J, Playfair JHL: Expression and rescuing of a cloned human tumour necrosis factor gene using an EBV-based shuttle cosmid vector. EMBO J 6: 355, 1987.
29. Kriegler M, Perez C, Defay K, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45-53, 1988.
30. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P: The transmembrane form of tumour necrosis factor (TNF) is the prime activating ligand of the 80 kDa TNF receptor. Cell 83: 793-802, 1995.
31. Kornbluth RS, Edington TS: Tumour necrosis factor production by human monocytes is a regulated event: induction of TNF-ot mediated cellular cytotoxicity by endotoxin. J Immunol 137: 2585-2591, 1986.
32. Decker T, Lohmann-Matthes ML, Gifford GE: Cell asso-dated Tumour Necrosis Factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138: 957-962, 1987.
33. + T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 177: 15751585, 1993.
34. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GHW, Chen EY, Goeddel DV: Cloning and expression of cDNAs for two distinct murine tumour necrosis receptors demonstrate one receptor is species specific. Proc Natl Acad Sei USA 88: 2830-2834, 1991.
35. Harris ED: Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 322: 1277-1289, 1990.
36. Zhumabekar T, Corbella P, Tolaini M, Kioussis D: Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods 185: 133-140, 1995.
37. Butler DM, Piccoli DS, Hart PH, Hamilton JA: Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. J Rheumatol 15: 14631470, 1988.
38. Gitter BD, Labus JM, Lees SL, Scheetz ME: Characteristics of human synovial fibroblast activation by IL-1 and TNFa. Immunology 66: 196-200, 1989.
39. Dayer J-M, Beutler B, Cerami A: Cachectin/tumour necrosis factor stimulates collagenase and prostoglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163, 1985.
40. 2 production by synovial cells. J Clin Invest 77: 645-648.
41. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370: 555-557, 1994.
42. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370: 218-220, 1994.